Is pediatric exclusivity working

Most drugs prescribed for children have not undergone pediatric testing; therefore, the data on dosing, efficacy and safety that are available for adults are not usually available for children. In 1997, Congress authorized the US FDA to grant extensions of marketing rights known as ‘pediatric exclusivity’ if FDA-requested pediatric trials are conducted. Although the program has been praised for stimulating an unprecedented number of drug studies in children, it has been criticized as an economic ‘windfall’ to prescription-drug manufacturers. The benefits of pediatric exclusivity are immeasurable towards improving child health, yet there exist many opportunities to improve the pediatric exclusivity program.

[1]  Eric L Eisenstein,et al.  Economic return of clinical trials performed under the pediatric exclusivity program. , 2007, JAMA.

[2]  J. Wit,et al.  Stimulation programs for pediatric drug research – do children really benefit? , 2007, European Journal of Pediatrics.

[3]  Robert M Califf,et al.  Peer-reviewed publication of clinical trials completed for pediatric exclusivity. , 2006, JAMA.

[4]  F. Djossou,et al.  Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Murphy,et al.  Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. , 2003, JAMA.

[6]  B. Lell,et al.  Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Wilson,et al.  An update on the therapeutic orphan. , 1999, Pediatrics.

[8]  G. Anabwani,et al.  Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. , 1999, The Pediatric infectious disease journal.

[9]  B. Lell,et al.  Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children , 1998, The Lancet.

[10]  B. Sadler,et al.  Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.